2022
DOI: 10.32604/biocell.2022.021661
|View full text |Cite
|
Sign up to set email alerts
|

Dexmedetomidine alleviates oxygen and glucose deprivation-induced apoptosis in mesenchymal stem cell via downregulation of MKP-1

Abstract: Bone marrow mesenchymal stem cell (MSC)-based therapy is a novel candidate for heart repair. But ischemiareperfusion injury leads to low viability of MSC. Dexmedetomidine (Dex) has been found to protect neurons against ischemia-reperfusion injury. It remains unknown if Dex could increase the viability of MSCs under ischemia. The present study is to observe the potential protective effect of Dex on MSCs under ischemia and its underlying mechanisms. Specific mRNAs related to myocardial ischemia in the GEO databa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 30 publications
(30 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?